Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Healthcare Biotechnology
Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP... see more

Recent & Breaking News (TSXV:HEM)

Hemostemix Announces Phase II Results Plus New Heart Study Demonstrating Statistically Significant Improvement in Ejection Fraction at 4 and 12 Months after ACP-01 Heart Injections

Newsfile August 30, 2022

Hemostemix (TSXV:HEM) closes first tranche of non-brokered private placement

John Ballem  August 23, 2022

Hemostemix Announces Closing of UNIT Private Placement

Newsfile August 22, 2022

Hemostemix (TSXV:HEM) announces $1.5M non-brokered private placement

John Ballem  August 19, 2022

Hemostemix Announces Unit Private Placement

Newsfile August 19, 2022

Hemostemix (TSXV:HEM) closes second tranche of non-brokered private placement

John Ballem  August 12, 2022

Hemostemix Announces Closing of Second Tranche of UNIT Private Placement

Newsfile August 12, 2022

Hemostemix Announces Closing of UNIT Private Placement

Newsfile June 22, 2022

Hemostemix Announces the Incorporation of PreCerv Inc. And a Global Field of Use License to NCP-01

Newsfile June 14, 2022

Hemostemix (TSXV:HEM) announces non-brokered private placement

John Ballem  May 20, 2022

Hemostemix Announces Financing

Newsfile May 19, 2022

Hemostemix Announces Pete Pavlin, P.Eng., Vice-President Operations

Newsfile May 19, 2022

Hemostemix Announces Rick Groome as Special Advisor to The CEO

Newsfile May 16, 2022

Hemostemix Announces Its Intellectual Property is Back Home

Newsfile May 10, 2022

Hemostemix Inc. (TSXV:HEM) closes $2.75M non-brokered debenture offering

John Ballem  April 25, 2022

Hemostemix Announces Closing of $2,750,000

Newsfile April 25, 2022

Hemostemix Inc. Announces Intellectual Property Due Diligence and Data Audit Completed

Newsfile April 12, 2022

Hemostemix Announces Settlement Agreement

Newsfile March 23, 2022

Hemostemix: Interest Payment on Convertible Debenture

Newsfile March 3, 2022

Hemostemix Announces $2,750,000 Convertible Debenture

Newsfile March 2, 2022